Skip to content
Atosiban
Tractocile (atosiban) is a protein pharmaceutical. Atosiban was first approved as Tractocile on 2000-01-20. It has been approved in Europe to treat premature birth. It is known to target vasopressin V1b receptor, vasopressin V1a receptor, oxytocin receptor, and vasopressin V2 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G02: Other gynecologicals in atc
— G02C: Other gynecologicals in atc
— G02CX: Other gynecologicals in atc
— G02CX01: Atosiban
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Premature obstetric laborD007752O60—231—6
Premature birthD047928EFO_0003917O60———112
InfertilityD007246EFO_0000545———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EndometriosisD004715EFO_0001065N80—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420T88.7————11
MeningomyeloceleD008591EFO_1001369Q05————11
Female infertilityD007247EFO_0008560N97————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameATOSIBAN
INNatosiban
Description
Atosiban, sold under the brand name Tractocile among others, is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985. Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent preterm birth in pregnant adult women.
Classification
Protein
Drug classoxytocin antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1
Identifiers
PDB—
CAS-ID90779-69-4
RxCUI59639
ChEMBL IDCHEMBL382301
ChEBI ID—
PubChem CID5311010
DrugBankDB09059
UNII ID081D12SI0Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AVPR1B
AVPR1B
AVPR1A
AVPR1A
OXTR
OXTR
AVPR2
AVPR2
Organism
Homo sapiens
Gene name
AVPR1B
Gene synonyms
AVPR3, VPR3
NCBI Gene ID
553
Protein name
vasopressin V1b receptor
Protein synonyms
Antidiuretic hormone receptor 1b, arginine vasopressin receptor 3, AVPR V1b, AVPR V3, pituitary vasopressin receptor 3, V1B receptor, Vasopressin V3 receptor
Uniprot ID
Q5TZ00
Mouse ortholog
Avpr1b (26361)
vasopressin V1b receptor (Q9WU02)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 685 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5 adverse events reported
View more details